whitepaper Whitepaper: Accelerating Gαq GPCR Drug Discovery with recognized and reliable tool 26 September 2016 | By Cisbio Bioassays Cisbio Bioassays has developed a GPCR platform based on the company’s HTRF® technology to measure second messenger accumulation...
news Using PD-L1 for immunotherapy? 21 September 2016 | By Abcam PD-L1 [28-8] (ab205921) is an ideal tool to quantify PD-L1 expression in patients for PD-1 based therapies....
article Hit-To-Lead In-Depth Focus 2016 20 September 2016 | By Drug Target Review In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...
news Attendee list released for the Orphan Drugs & Rare Diseases 2016 13 September 2016 | By SMi SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...
article Zebrafish early-life stages as neurological screening and detection tools 6 September 2016 | By Martina Fenske (Fraunhofer IME), Sheraz Gul (Fraunhofer IME) Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
article Hit-to-lead in drug discovery 4 September 2016 | By Douglas B. Kitchen (Albany Molecular Research Inc.), Mark Wolf (Albany Molecular Research Inc.) Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...
whitepaper App note: HTRF technology essentials to boost your research 23 August 2016 | By Cisbio Bioassays In this application note, learn how to reduce time and sample consumption while achieving highly reproducible results from your assays with HTRF technology...
news Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium 10 August 2016 | By Charles River Laboratories Charles River Laboratories announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium...
product Bio-Rad CFX96 Touch™ Real-Time PCR Detection System 4 August 2016 | By Bio-Rad Laboratories The CFX96™ Optical Reaction Module converts the C1000 Touch™ Thermal Cycler chassis into the powerful and precise CFX96 Touch Real-Time PCR Detection System...
news Targeting Cancer with 5 key spotlight sessions on the latest therapy breakthroughs 21 July 2016 | By SMi Group SMi's 5th annual Cancer Vaccines event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn...
news A*STAR and MSD team up to advance peptide therapeutics 19 July 2016 | By Niamh Louise Marriott A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...
news Human Cancer Models Initiative could transform research 11 July 2016 | By Victoria White, Digital Content Producer An international project to develop a large, globally accessible, bank of new cancer models for the research community launches today...
news Scientists discover basal cell carcinoma cell of origin 8 July 2016 | By Victoria White, Digital Content Producer Scientists have identified the 'cell of origin' in basal cell carcinoma and followed the chain of events that lead to the growth of these invasive tumours...
news Scientists use a “big data” approach to precision medicine 7 July 2016 | By Victoria White, Digital Content Producer Researchers have compared genetic mutations in tumours to those in cancer cell lines and then tested the cell lines' responses to therapeutic compounds...
news NEAT1 identified as potential therapeutic target in the fight against cancer 4 July 2016 | By Victoria White, Digital Content Producer Scientists have shown that NEAT1, a non-coding RNA, plays an important role in the survival of highly dividing cells - and in particular of cancer cells...